Hilleman Laboratories is preparing to manufacture clinical-trial doses of an investigational Bundibugyo Ebola vaccine with $8.5 million in funding from the Coalition for Epidemic Preparedness Innovations.
The outbreak in the Democratic Republic of Congo has caused 1,487 deaths from 3,360 confirmed cases as of July 29, with no currently approved vaccines for this specific virus strain.
Merck plans to provide technical expertise to produce doses for early-stage trials by the end of 2026, with potential for technology transfer to larger manufacturers if demand increases.